Health Technology Assessment Frameworks and Policies

Many thanks for sharing this descriptive overview of Health Technology assessment (HTA). I absolutely agree that early HTA is crucial for guiding efficient adoption of latest technologies especially in geographically difficult to reach population. The comparison outlined among India's HTA and US ICER demonstrate how varied systems balance equity, cost-effectiveness and evidence. 

Reference: 

Rodriguez Llorian E, Waliji LA, Dragojlovic N, Michaux KD, Nagase F, Lynd LD. Frameworks for Health Technology Assessment at an Early Stage of Product Development: A Review and Roadmap to Guide Applications. Value Health. 2023 Aug;26(8):1258-1269. doi: 10.1016/j.jval.2023.03.009. Epub 2023 Mar 27. PMID: 36990207.

World Health Organization. Resolution WHA 67.23. (2013). Health Intervention and Technology Assessment in WHO. [Online, Cited 11 October 2018]. Available: //apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R23-en.pdf.

Health Technology Assessment (HTA) is a transdisciplinary process of evaluating the various aspects of emerging health technologies in order to make health systems more efficient, equitable, and sustainable. It involves evaluating the medical, economic and social aspects of medicines, devices, diagnostics and digital interventions (Prinja et al., 2020).

Numerous HTA frameworks have been developed globally, in order to assess the cost-effectiveness, safety, regulatory compliance, ethical and social issues associated with latest health technology. Europe’s EUnetHTA provides a standardized model, while the UK’s NICE applies cost-effectiveness thresholds to guide coverage. In Canada, CADTH and INESSS inform provincial reimbursement, and in the U.S., ICER provides independent cost-effectiveness reports. The WHO promotes HTA globally, especially to support low- and middle-income countries. Policies vary across countries. India’s DHR-HTAIn supports Ayushman Bharat, and China is expanding HTA to manage rising healthcare costs (Dabak et al., 2018).

Emerging global trends include value-based healthcare (linking payments to outcomes), early HTA, stronger patient involvement, digital health assessments for tools like AI and telemedicine, and a focus on equity to reduce health disparities. Together, HTA frameworks and policies ensure that new technologies adopted by health systems are safe, effective, affordable, and fair (Otte et al., 2024).

References

Dabak, S. V., Pilasant, S., Mehndiratta, A., Downey, L. E., Cluzeau, F., Chalkidou, K., Luz, A. C. G., Youngkong, S., & Teerawattananon, Y. (2018). Budgeting for a billion: Applying health technology assessment (HTA) for universal health coverage in India. Health Research Policy and Systems, 16(1), 115. //doi.org/10.1186/s12961-018-0378-x

Otte, M., Dauben, H. P., Ahn, J., Gutierrez Ibarluzea, I., Drummond, M., Simoens, S., Kaló, Z., & Suh, D. C. (2024). Value based healthcare and Health Technology Assessment for emerging market countries: Joint efforts to overcome barriers. Expert Review of Pharmacoeconomics & Outcomes Research, 24(9), 1061–1066. //doi.org/10.1080/14737167.2024.2398482

Prinja, S., Rajsekhar, K., & Gauba, V. K. (2020). Health technology assessment in India: Reflection & future roadmap. The Indian Journal of Medical Research, 152(5), 444–447. //doi.org/10.4103/ijmr.IJMR_115_19

I think that Health Technology Assessment (HTA) is a critical means of ensuring that medical innovations do not merely add expense, but actually deliver value. What impresses me most is the way HTA weighs not just clinical and cost-effectiveness, but ethical and social dimensions that get lost in the decision-making process (WHO, 2021).

Today’s rapid introduction of innovative technologies, particularly digital health tools, AI, and precision medicine, underscores the significance of early HTA. As mentioned earlier, eHTA can protect against the waste of funds on potentially unsustainable, ineffective, or inequitable technologies by evaluating them early, involving stakeholders, and using adaptable approaches(Rodriguez Llorian et al., 2023).

It is reassuring to policy makers when they see efforts such as HTAIn in India and ICER in the U.S., as these illustrate how HTA can be localized without straying from global criteria (HTAIn, n.d.; ICER, 2018). Balancing equity in access remains a grave concern, for a certain “technology” could be cost-effective on the whole, and still be of questionable value since it remains out of reach to disadvantaged groups. 

In addition to guiding the distribution of resources, HTA and eHTA bring into the fore important questions of equity and long-term viability with regard to new health innovations. For me, HTA represents the nexus of health technology and public health, particularly in the context of universal health coverage (INAHTA, 2025).

 REFERENCES:

• (2021). Health technology assessment – Global. World Health Organization.
• Rodriguez Llorian, E., Waliji, L. A., Dragojlovic, N., Michaux, K. D., Nagase, F., & Lynd, L. D. (2023). Frameworks for Health Technology Assessment at an Early Stage of Product Development. Value in Health, 26(8), 1258–1269. //doi.org/10.1016/j.jval.2023.03.009
• (n.d.). HTAIn Manual. Department of Health Research, India. //htain.dhr.gov.in/images/pdf/HTAIn_Manual.pdf
• (2018). Guide to Understanding Health Technology Assessment. Institute for Clinical and Economic Review. //icer.org/wp-content/uploads/2020/10/ICER-Guide-to-Understanding-Health-Technology-Assessment-6.19.18.pdf
• (2025). International Network of Agencies for Health Technology Assessment. //www.inahta.org/